

1 Decision-making in acute viral bronchiolitis:
2 a universal guideline and a publication gap

3

4 Jochen Meyburg ¹, Markus Ries ^{2*}

5

6 ¹ Department of General Pediatrics and Pediatric Intensive Care, Center of Pediatric and
7 Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany

8 ² Pediatric Neurology and Metabolic Medicine, Center of Pediatric and Adolescent
9 Medicine, University Hospital Heidelberg, Heidelberg, Germany

10

11 * Corresponding author

12 E-mail: markus.ries@uni-heidelberg.de (MR)

13 **Abstract**

14 Background: Acute viral bronchiolitis is very common in infants and children up to 2 years.
15 Some patients develop serious respiratory symptoms and need to be hospitalized. In
16 2014, the American Academy of Pediatrics (AAP) published a guideline on acute
17 bronchiolitis which has gained global acceptance. We hypothesized that a publication gap,
18 which is increasingly perceived in clinical medicine, might have also affected these
19 universal recommendations.

20 Methods: We determined the proportion of published and unpublished studies registered
21 at ClinicalTrials.gov that were marked as completed by October 1st 2018. The major trial
22 and literature databases were used to search for publications. In addition, the study
23 investigators were contacted directly.

24 Results: Of the 69 registered studies on the treatment of acute viral bronchiolitis, only 50
25 (72%) have been published by November 2019. Published trials contained data from
26 n=9403 patients, whereas n=4687 patients were enrolled in unpublished trials. Median
27 time to publication was 20 months, and only 8 of 50 trials were published within 12 months
28 after completion. Only 40% of the clinical trials that were completed after the release of the
29 AAP guideline were subsequently published as compared to 80% before 2014.

30 Conclusion: There is a significant publication gap regarding therapy of acute viral
31 bronchiolitis that may have influenced certain recommendations of the AAP guideline. In
32 turn, recommendations of the guideline might have discouraged investigators to publish
33 their results after its release.

34

35 **Introduction**

36 Viral bronchiolitis is a very common cause of outpatient visits in children younger than 2
37 years and accounts for 16% of hospitalizations in this age group [1]. Although several
38 viruses may cause bronchiolitis, respiratory syncytial virus (RSV) is responsible for about
39 80% of infections, especially in infants [2]. Whereas the infection has a benign and self-
40 limiting course in the majority of affected children, it can be a serious and potentially life-
41 threatening disease in some patients with complex underlying diseases such as congenital
42 heart disease or bronchopulmonary dysplasia [3].

43 Unfortunately, a causative treatment of acute viral bronchiolitis does not exist due to its
44 special pathophysiology. Infection of the terminal bronchiolar epithelial cells causes
45 edema, excessive formation of mucus, and eventually necrosis of bronchiolar epithelia.
46 Hence, therapy is restricted to symptomatic measures until the respiratory epithelia have
47 regenerated. Such supportive care may include a variety of medications, including chest
48 physiotherapy and breathing aids, and different caregivers have been using different
49 approaches in the past. In 2014, a landmark paper by the American Association of
50 Pediatrics was published which has been regarded a universal clinical practice guideline
51 since [4]. Surprising to many, the AAP guideline does not support the routine use of
52 commonly used therapies such as chest physiotherapy, bronchodilators (e.g. albuterol, or
53 salbutamol), epinephrine inhalation, corticosteroids, or antibiotics. Recommendations were
54 only made for administration of nebulized hypertonic saline and nasogastral or intravenous
55 fluids, both in hospitalized children only.

56 The AAP guideline was developed by a group of very renowned experts based on
57 published study results. However, it is increasingly noted that the results of many clinical
58 trials are not reported in a timely manner or not reported at all. Such selective reporting of
59 study results, known as publication bias or publication gap has been observed in a various

60 fields of pediatrics [5-8]. Given the discrepancy between the few treatment options
61 recommended by the AAP guideline and the widespread use of various other therapeutic
62 approaches, we were wondering whether the actual decision making might be influenced
63 by such a publication gap.

64

65 **Methods**

66 **Identification of clinical trials**

67 To identify registered clinical trials on bronchiolitis reported as completed, the
68 ClinicalTrials.gov database provided by the U.S. National Library of Medicine was
69 assessed. Search criteria were: keyword “bronchiolitis” with the query selection
70 parameters “completed studies” and “child (0-17 years)”. Close of database was October
71 1st 2019. Data were downloaded for further analysis.

72 **Search for publications of completed trials**

73 To identify publications related to the registered and completed trials, ClinicalTrials.gov,
74 PubMed and Google Scholar were searched for NCT number, study title, principal
75 investigator, study sponsor and keywords generated from the study title. If no respective
76 publication was found, the principal investigators were contacted by email and/or social
77 networks (ResearchGate and/or facebook) and asked to provide information whether the
78 study was published in a source not covered by PubMed or Google Scholar.

79

80 **Data analysis**

81 The STROBE criteria (STrengthening the Reporting of OBservational studies in
82 Epidemiology) were applied for design and analysis of this study [9]. Data were analyzed
83 for age and number of participants, gender, study type, study design, condition,
84 intervention, availability of study results, completion date, publication date, sponsor and
85 country of sponsor. Trials were categorized into 11 groups according to their main
86 research topic. Time to publication was calculated as the difference in months between
87 study completion date and publication date. Missing data were not imputed. All statistical
88 analyses were performed in SPSS 20 (IBM Corporations, Armonk, New York) using
89 standard methods for descriptive statistics.

90

91 **Results**

92 **Publication status of studies**

93 We identified a total of 124 studies that were reported as completed in the
94 ClinicalTrials.gov database. Thirty of these studies were not related to viral bronchiolitis,
95 the majority of which studies on bronchiolitis obliterans following lung transplantation. Of
96 the remaining 94 clinical trials, 71 investigated therapeutic interventions in acute viral
97 bronchiolitis. Two of these studies, both unpublished, were completed less than one year
98 before close of the database. Because the U.S. Food and Drug Administration (FDA)
99 allows a time frame of one year between completion and publication of the study as
100 specified in the FDA Drug Administration Amendments Act (FDAAA) [10], these two
101 studies were excluded from the analysis. Of the remaining 69 studies, 50 were published
102 and 19 were unpublished. Among them were two clinical trials that had been reported as
103 conference papers only. One of these abstracts gave sufficient data that supported a

104 therapeutic recommendation. We therefore regarded the study as published. The other
105 abstract, however, only contained vague information on the study results, therefore we
106 considered the study unpublished. All but one principal investigator of the unpublished
107 studies could be contacted by email or social networks. Of these 18 authors, three replied
108 and confirmed that the study results had not been published yet (Fig 1). Publication rates
109 considerably varied between different countries of the sponsor (Table 1) and main topics
110 of the investigations (Table 2).

111 The numbers of published and unpublished studies for each year of study completion
112 (2003 – 2018) is shown in Fig 2. While 80% of the registered clinical trials that had been
113 completed up to 2014 have been subsequently published, it is noticeable that almost 40%
114 of the studies completed after the release of the AAP guideline still remain unpublished.

115 **Patient numbers**

116 All studies involved both genders. Published trials contained data from n=9403 patients,
117 whereas n=4687 patients were enrolled in unpublished trials. Median size of published
118 trials was 93 (IQR 48-175), range 12-1636, whereas median size of unpublished trials was
119 94 (IQR 60-146), range 33-2580 participants. Fig 3 shows that in some years, the number
120 of patients enrolled in unpublished studies significantly exceeded those in published
121 studies.

122 **Time to publication**

123 Median time to publication was 20 (IQR 13-31), range 2 to 58 months. No trend could be
124 identified that either older or more recent studies were published faster, and only 8 of 50
125 trials were published within 12 months after completion as warranted by the FDAAA (Fig
126 4).

127

128 **Discussion**

129 Few other guidelines have gained quasi universal global acceptance as the 2014 AAP
130 guideline on bronchiolitis [4]. Therefore, our analysis of the registered clinical trials on the
131 treatment of acute viral bronchiolitis had two key questions: (1) Could a publication gap
132 have influenced the guideline's recommendations and (2) did the guideline affect the
133 publication status of subsequent clinical trials?

134 For the first part of our analysis, only clinical trials the results of which could have been
135 available prior to completion of the AAP guideline were taken into account. Few
136 therapeutic options have been recommended in the guideline: oxygen (given an oxygen
137 saturation below 90%), adequate fluid intake, and inhalation with hypertonic saline. No
138 unpublished studies on supplemental oxygen or fluid intake were identified. However, two
139 studies on the use of hypertonic saline have been completed, but not published before the
140 AAP guideline was released. The guideline gives a weak recommendation to administer
141 nebulized hypertonic saline to infants and children hospitalized for bronchiolitis, but does
142 not recommend its use in the emergency department (ED). One of the unpublished studies
143 compared hospitalization rates of infants presenting to the ED with bronchiolitis during the
144 year of use of nebulized hypertonic saline versus the two previous years when nebulized
145 hypertonic saline was not used in a single center in France (NCT01460524). This study
146 alone enrolled 2580 patients, which is about 10% more than the sum of all patients (2294)
147 from 14 studies analyzed in the AAP guideline. So the results of this trial might well have
148 affected the recommendations for the use of hypertonic saline in the ED. The other
149 unpublished clinical trial (NCT01238848) studied the effects of hypertonic saline versus
150 normal saline in combination with albuterol in 82 children already hospitalized for moderate
151 bronchiolitis. It is unlikely that this study would have had an impact on the AAP
152 recommendations.

153 The AAP guideline explicitly advises against various other therapeutic measures:
154 bronchodilators (albuterol or salbutamol), antibiotics, epinephrine, steroids, and chest
155 physiotherapy. In our analysis, we did not find unpublished studies on the use of
156 bronchodilators or antibiotics. One unpublished clinical trial with 82 participants
157 (NCT00435994) investigated the production of VEGF from nasal washing after inhalation
158 with epinephrine in infants with bronchiolitis and healthy controls, respectively. Thus,
159 published results of this study would not have affected the guideline. We identified one
160 unpublished trial with 94 patients on the use of steroids in acute bronchiolitis
161 (NCT02571517). In this study, children that had been hospitalized for moderate to severe
162 bronchiolitis received intravenous methylprednisolone and/or oral prednisolone for seven
163 days. Several clinical endpoints (disease severity scores, chest X-rays, admission to the
164 PICU, need for mechanical ventilation) were defined as primary and secondary outcomes
165 on day 7. Interestingly, the AAP guideline focuses on hospital admission rates regarding
166 the use of steroids, but does not give evidence for a lack of efficiency in children already
167 hospitalized for bronchiolitis. Thus, the results of this unpublished study might have had an
168 impact on the official recommendations.

169 There are also therapies for bronchiolitis on which clinical trials are listed in the register,
170 but that are not addressed in the guideline. Montelukast is mentioned in Appendix 1 as a
171 MedLine search term, but its use is not discussed in the text. The Clinical trials database
172 lists a total of six studies on montelukast in bronchiolitis, two of which only investigated the
173 pharmacokinetics. Of the remaining four clinical trials, two have been published. A small
174 study with 53 participants found no benefit of montelukast in patients with acute disease
175 [11]. A second multicenter study with 1125 participants focused on post-RSV bronchiolitis
176 during an observation periods of 24 weeks [12]. Again, beneficial effects of montelukast
177 were not observed. On the other hand, we identified two unpublished randomized
178 controlled trials on the use of montelukast in acute bronchiolitis, both with significant

179 numbers of participants (NCT01370187: n=146; NCT00863317: n=141). It can be
180 speculated that the AAP would have advised against montelukast in the guideline if the
181 results of the two unpublished studies had come to the same conclusion as the published
182 ones.

183 Finally, we analyzed the database to find out whether the AAP guideline might have
184 affected the publication status of clinical trials in children with acute bronchiolitis. It was
185 impressive that the rate of unpublished studies doubled after the release of the guideline.
186 Among the unpublished studies completed after 2014, four were on the use of nebulized
187 hypertonic saline (NCT02538458, NCT02233985, NCT03143231, NCT03614273). It is
188 likely that given the guideline's at least weak recommendation to use it in hospitalized
189 patients, there is a publication bias regarding positive results. In other words, the mere
190 confirmation of the official recommendations may not have been worth the effort of
191 publication. The same may hold true for two other unpublished studies on the combined
192 use of hypertonic saline, dexamethasone, and epinephrine (NCT01834820) and chest
193 physiotherapy, respectively (NCT02853838). On the other hand, there are possible
194 therapies that might be addressed in a revision of the guideline in the near future, such as
195 the use of high flow nasal cannula (HFNC). Since there are several clinical studies that
196 found positive effects of HFNC in acute bronchiolitis [13-15], maybe this will motivate the
197 principal investigators to publish the results of three recent studies that are yet
198 unpublished (NCT02791711, NCT01498094, NCT02856165).

199 In conclusion, publication bias or publication gap is an ubiquitous issue in clinical science.
200 Increasingly, study results are not reported in a timely manner, or not published at all. The
201 therapy of acute viral bronchiolitis is a major task for pediatricians during the winter
202 season, and it is supported by a highly appreciated guideline that is followed worldwide.
203 But even this guideline might have been affected by a publication gap and in turn might
204 have discouraged investigators to publish their results after its release.

205 **Table 1: Countries of the sponsor**

206 Published (n=50) and unpublished (n=19) completed therapeutic studies on viral
207 bronchiolitis by country

Countries	Published studies (n)	Unpublished studies (n)
Mexico	0	2
Argentina, Bangladesh, Chile, India, Iran, Lebanon	0	1
Australia, Belgium, China, Denmark, Finland, Nepal, Netherlands, Switzerland, Thailand, United Kingdom	1	0
Egypt	1	1
Spain	2	1
Brazil, Italy, Turkey	2	0
Canada	3	1
France	5	4
Israel	5	1
Qatar	5	0
United States	13	3

208 **Table 2: Main study topics**

209 Publication status of studies registered as completed on ClinicalTrials.gov involving children with
210 bronchiolitis.

Issue	Overall number of studies	Number and percentage of published studies	Number of patients enrolled in unpublished studies
Hypertonic Saline	23	16 (70%)	3154
Respiratory Support (Oxygen, HFNC, CPAP)	10	7 (70%)	380
Other drugs	7	4 (57%)	440
Physiotherapy	7	6 (86%)	204
Epinephrine	6	3 (50%)	239
Montelukast	6	4 (67%)	287
Steroids	6	4 (67%)	214
Gases (NO, Helium)	4	3 (75%)	69
Furosemide	2	2 (100%)	0
Magnesium	2	2 (100%)	0
Organisation/Isolation	2	2 (100%)	2


211 HFNC: High flow nasal cannula, CPAP: continuous positive airway pressure, NO: nitric oxide.

212

213 **Figures**


214

215 Figure 1: Flowsheet: details of the study selection process




216

217 Figure 2: Distribution of published (n=50) and unpublished (n=19) trials by year of
218 completion. Close of database was October 1st 2019.



219

220 Figure 3: Distribution of patient count stratified by publication status and year. Close of
221 database was October 1st 2019.



222

223

224


225

226

227

228

229 Figure 4: Time to publication (time between completion of the trial and publication of
230 results) in months by year of completion. Close of database was October 1st
231 2019.



232

233 **References**

- 234 1. Hasegawa K, Tsugawa Y, Brown DF, Mansbach JM, Camargo CA, Jr. Trends in
235 bronchiolitis hospitalizations in the United States, 2000-2009. *Pediatrics*.
236 2013;132(1):28-36. doi: 10.1542/peds.2012-3877. PubMed PMID: 23733801; PubMed
237 Central PMCID: PMCPMC3691534.
- 238 2. Meissner HC. Viral Bronchiolitis in Children. *N Engl J Med*. 2016;374(1):62-72. doi:
239 10.1056/NEJMra1413456. PubMed PMID: 26735994.
- 240 3. Byington CL, Wilkes J, Korgenski K, Sheng X. Respiratory syncytial virus-associated
241 mortality in hospitalized infants and young children. *Pediatrics*. 2015;135(1):e24-31.
242 doi: 10.1542/peds.2014-2151. PubMed PMID: 25489019; PubMed Central PMCID:
243 PMCPMC4279071.
- 244 4. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al.
245 Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis.
246 *Pediatrics*. 2014;134(5):e1474-502. doi: 10.1542/peds.2014-2742. PubMed PMID:
247 25349312.
- 248 5. Breil T, Boettcher M, Hoffmann GF, Ries M. Publication status of completed registered
249 studies in paediatric appendicitis: a cross-sectional analysis. *BMJ Open*.
250 2018;8(7):e021684. doi: 10.1136/bmjopen-2018-021684. PubMed PMID: 30012791;
251 PubMed Central PMCID: PMCPMC6082464.
- 252 6. Patry C, Kranig S, Rafat N, Schaible T, Toenshoff B, Hoffmann GF, et al. Cross-
253 sectional analysis on publication status and age representation of clinical studies
254 addressing mechanical ventilation and ventilator-induced lung injury in infants and
255 children. *BMJ Open*. 2018;8(11):e023524. doi: 10.1136/bmjopen-2018-023524.
256 PubMed PMID: 30455388; PubMed Central PMCID: PMCPMC6252714.
- 257 7. Lampert A, Hoffmann GF, Ries M. Ten Years after the International Committee of
258 Medical Journal Editors' Clinical Trial Registration Initiative, One Quarter of Phase 3
259 Pediatric Epilepsy Clinical Trials Still Remain Unpublished: A Cross Sectional
260 Analysis. *PLoS One*. 2016;11(1):e0144973. doi: 10.1371/journal.pone.0144973.
261 PubMed PMID: 26735955; PubMed Central PMCID: PMCPMC4703397.
- 262 8. Mechler K, Hoffmann GF, Dittmann RW, Ries M. Defining the hidden evidence in
263 autism research. Forty per cent of rigorously designed clinical trials remain

- 264 unpublished - a cross-sectional analysis. *Int J Methods Psychiatr Res.* 2017;26(4). doi:
265 10.1002/mpr.1546. PubMed PMID: 27862603.
- 266 9. Vandenberghe JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et
267 al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE):
268 explanation and elaboration. *Int J Surg.* 2014;12(12):1500-24. doi:
269 10.1016/j.ijsu.2014.07.014. PubMed PMID: 25046751.
- 270 10. FDAAA. Sec. 801. Expanded clinical trial registry data bank 2007 2007. Available
271 from: [https://www.govinfo.gov/content/pkg/PLAW-110publ85/pdf/PLAW-](https://www.govinfo.gov/content/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf#page=82)
272 [110publ85.pdf#page=82](https://www.govinfo.gov/content/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf#page=82).
- 273 11. Amirav I, Luder AS, Kruger N, Borovitch Y, Babai I, Miron D, et al. A double-blind,
274 placebo-controlled, randomized trial of montelukast for acute bronchiolitis. *Pediatrics.*
275 2008;122(6):e1249-55. Epub 2008/11/06. doi: 10.1542/peds.2008-1744. PubMed
276 PMID: 18984650.
- 277 12. Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, et al. Study of
278 montelukast for the treatment of respiratory symptoms of post-respiratory syncytial
279 virus bronchiolitis in children. *Am J Respir Crit Care Med.* 2008;178(8):854-60. Epub
280 2008/06/28. doi: 10.1164/rccm.200706-910OC. PubMed PMID: 18583576.
- 281 13. Vahlkvist S, Jurgensen L, la Cour A, Markoew S, Petersen TH, Kofoed PE. High flow
282 nasal cannula and continuous positive airway pressure therapy in treatment of viral
283 bronchiolitis: a randomized clinical trial. *Eur J Pediatr.* 2020;179(3):513-8. Epub
284 2019/12/13. doi: 10.1007/s00431-019-03533-2. PubMed PMID: 31828528.
- 285 14. Ergul AB, Caliskan E, Samsa H, Gokcek I, Kaya A, Zararsiz GE, et al. Using a high-
286 flow nasal cannula provides superior results to OxyMask delivery in moderate to
287 severe bronchiolitis: a randomized controlled study. *Eur J Pediatr.* 2018;177(8):1299-
288 307. Epub 2018/06/20. doi: 10.1007/s00431-018-3191-1. PubMed PMID: 29915869.
- 289 15. Chen DY, Zee ED, Gildengorin G, Fong EW. A pilot study of heated and humidified
290 low flow oxygen therapy: An assessment in infants with mild and moderate
291 bronchiolitis (HHOT AIR study). *Pediatr Pulmonol.* 2019;54(5):620-7. Epub
292 2019/03/20. doi: 10.1002/ppul.24267. PubMed PMID: 30887708.